All Posts

The FDA's draft guidance, Potency Assurance for Cellular and Gene Therapy Products, represents an important shift in how cell and gene therapy developers should approach potency throughout product development. Although the guidance applies broadly across the field, several recommendations are especially relevant to ocular AAV programs. Rather than viewing potency as a single laboratory assay, the FDA emphasizes a comprehensive potency assurance strategy that evolves with the